{
  "experiment_id": "625fe1450ca6754ee3e4b81d7c177dc7",
  "task_name": "translation_of_exact_synonyms",
  "task_hash": "8ad16d30616e7d6242f8204a96cf0019",
  "model_id": "google/gemini-3-pro-preview",
  "system_instructions": "You are a metadata curation assistant. Your task is to help improve and correct metadata \naccording to the specific instructions provided for each task. Be precise, accurate, and \nfollow the guidelines carefully.\n",
  "temperature": 0.0,
  "thinking": false,
  "tools": [],
  "timestamp": "2025-11-19T20:31:44.984423",
  "task_result": {
    "task_name": "translation_of_exact_synonyms",
    "num_samples": 10,
    "results": [
      {
        "sample_index": 0,
        "input": {
          "diagnosis": "NF1",
          "assay": "WEX",
          "tumorType": "pNF"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Plexiform Neurofibroma\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2561,
            "outputTokens": 679,
            "totalTokens": 3240
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584208-jd33UWgtAWjYY1B1iAzo",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763584208,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Plexiform Neurofibroma\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Defining Terminology**\n\nI've begun analyzing the provided target schema and the input data. The initial focus is on mapping synonyms within the input to the standard terms in the target schema. I'm prioritizing accuracy in this translation process, ensuring the data integrity remains intact. The \"diagnosis,\" \"assay,\" and \"tumorType\" fields are the focal points right now.\n\n\n**Identifying the Mapping**\n\nI've just finished the first mapping, with \"NF1\" from the input correctly translating to \"Neurofibromatosis type 1\" in the schema. Now, moving on to the `assay` field, \"WEX\" seems to stand for \"Whole Exome Sequencing\". I'm validating this and looking for an exact match within the allowed values to ensure data fidelity during the migration.\n\n\n**Verifying Data Integrity**\n\nI've confirmed the mappings for `tumorType`. \"pNF\" maps directly to the schema's \"Plexiform Neurofibroma\", completing the crucial field alignments. With all key fields now reconciled, I'm verifying the final output structure, checking its compliance with all existing schema constraints. The json object is now being validated against the schemas. All signs point to a successful translation, and I will be delivering the final structure momentarily.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Defining Terminology**\n\nI've begun analyzing the provided target schema and the input data. The initial focus is on mapping synonyms within the input to the standard terms in the target schema. I'm prioritizing accuracy in this translation process, ensuring the data integrity remains intact. The \"diagnosis,\" \"assay,\" and \"tumorType\" fields are the focal points right now.\n\n\n**Identifying the Mapping**\n\nI've just finished the first mapping, with \"NF1\" from the input correctly translating to \"Neurofibromatosis type 1\" in the schema. Now, moving on to the `assay` field, \"WEX\" seems to stand for \"Whole Exome Sequencing\". I'm validating this and looking for an exact match within the allowed values to ensure data fidelity during the migration.\n\n\n**Verifying Data Integrity**\n\nI've confirmed the mappings for `tumorType`. \"pNF\" maps directly to the schema's \"Plexiform Neurofibroma\", completing the crucial field alignments. With all key fields now reconciled, I'm verifying the final output structure, checking its compliance with all existing schema constraints. The json object is now being validated against the schemas. All signs point to a successful translation, and I will be delivering the final structure momentarily.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2561,
              "completion_tokens": 679,
              "total_tokens": 3240,
              "prompt_tokens_details": {
                "cached_tokens": 0
              },
              "completion_tokens_details": {
                "reasoning_tokens": 632,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Plexiform Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2561,
          "output_tokens": 679,
          "total_tokens": 3240
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 1,
        "input": {
          "diagnosis": "neurofibromatosis type 1",
          "assay": "WES",
          "tumorType": "MPNST"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Malignant Peripheral Nerve Sheath Tumor\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2566,
            "outputTokens": 530,
            "totalTokens": 3096
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584215-V4iqJBjJ0QfY0MNwCNKv",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763584215,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Malignant Peripheral Nerve Sheath Tumor\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Standardizing Metadata Terms**\n\nI'm currently working on translating synonyms to standard terms, specifically focusing on the diagnosis, assay, and tumorType fields. My goal is to ensure consistency and compliance with the Target Schema. I've successfully identified the need for standardization, and am making progress identifying the appropriate standard terms for each of the provided values.\n\n\n**Analyzing Schema Compliance**\n\nI've determined the exact actions to take for each field. For the `diagnosis` field, it's a simple capitalization fix.  However, for both `assay` (\"WES\") and `tumorType` (\"MPNST\"), I'll map the acronyms to their full, corresponding terms defined in the schema, namely \"whole exome sequencing\" and \"Malignant Peripheral Nerve Sheath Tumor\" respectively, based on my understanding. I've also verified that the resulting terms are present in the relevant schema enums.\n\n\n**Finalizing Mapping Outputs**\n\nI'm now in the process of finalizing the output structure based on the standardization. I've confirmed that \"whole exome sequencing\" and \"Malignant Peripheral Nerve Sheath Tumor\" are present in the appropriate schema enums. The output will be a JSON structure with standardized terms for diagnosis, assay, and tumorType. I'm focusing on ensuring data integrity and correct formatting for the final report. The output adheres to the Target Schema, which is a success.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Standardizing Metadata Terms**\n\nI'm currently working on translating synonyms to standard terms, specifically focusing on the diagnosis, assay, and tumorType fields. My goal is to ensure consistency and compliance with the Target Schema. I've successfully identified the need for standardization, and am making progress identifying the appropriate standard terms for each of the provided values.\n\n\n**Analyzing Schema Compliance**\n\nI've determined the exact actions to take for each field. For the `diagnosis` field, it's a simple capitalization fix.  However, for both `assay` (\"WES\") and `tumorType` (\"MPNST\"), I'll map the acronyms to their full, corresponding terms defined in the schema, namely \"whole exome sequencing\" and \"Malignant Peripheral Nerve Sheath Tumor\" respectively, based on my understanding. I've also verified that the resulting terms are present in the relevant schema enums.\n\n\n**Finalizing Mapping Outputs**\n\nI'm now in the process of finalizing the output structure based on the standardization. I've confirmed that \"whole exome sequencing\" and \"Malignant Peripheral Nerve Sheath Tumor\" are present in the appropriate schema enums. The output will be a JSON structure with standardized terms for diagnosis, assay, and tumorType. I'm focusing on ensuring data integrity and correct formatting for the final report. The output adheres to the Target Schema, which is a success.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2566,
              "completion_tokens": 530,
              "total_tokens": 3096,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 481,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 2566,
          "output_tokens": 530,
          "total_tokens": 3096
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 2,
        "input": {
          "diagnosis": "ORPHA:636",
          "assay": "WGS",
          "tumorType": "MPN tumor"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Malignant Peripheral Nerve Sheath Tumor\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2566,
            "outputTokens": 1644,
            "totalTokens": 4210
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584220-w07YnQfSapX9xp7C6w8T",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763584220,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole genome sequencing\",\n  \"tumorType\": \"Malignant Peripheral Nerve Sheath Tumor\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Defining the Correction Process**\n\nI'm currently focused on defining the correction process for metadata. I'm analyzing how to map the existing data to a target schema, specifically tackling the issue of correcting metadata values in a JSON object. The input JSON and the Target Schema are key elements of this process.\n\n\n**Validating Input Against Schema**\n\nI've been working on validating input data against the target schema, focusing on specific fields.  For the `diagnosis` field, \"ORPHA:636\" correctly maps to \"Neurofibromatosis type 1\".  Similarly, I've confirmed that \"WGS\" in the `assay` field maps to \"whole genome sequencing\".  Next up: the `tumor` field analysis.\n\n\n**Mapping Tumor Types Precisely**\n\nI'm now diving into the `tumor` field, specifically \"MPN tumor.\" Based on the target schema and the context of Neurofibromatosis, \"Malignant Peripheral Nerve Sheath Tumor\" (MPNST) appears to be the most likely mapping. While \"MPN\" can refer to Myeloproliferative Neoplasms (and that is in the schema), the tumor context strongly suggests MPNST, and I want to confirm that. I'm investigating the possibility of \"MPN tumor\" being shorthand or a typo, as it's common in this domain. I'm also ensuring that I don't overlook \"Juvenile Myelomonocytic Leukemia\" (JMML), another MPN, which might be in the schema also. I'll evaluate the full list of options again for confirmation.\n\n\n**Clarifying Tumor Ambiguity**\n\nI'm now wrestling with the \"MPN tumor\" mapping. Given the NF1 diagnosis, both MPNST and JMML are possibilities. Analyzing the abbreviation \"MPN tumor\", my current thinking leans toward \"Malignant Peripheral Nerve Sheath Tumor\" (MPNST) as the intended target, particularly since \"tumor\" implies a solid mass in these schemas, and MPNST is more commonly abbreviated this way. I've re-reviewed the schema and mappings to solidify this.\n\n\n**Solidifying the Tumor Mapping**\n\nI've been meticulously reviewing the \"MPN tumor\" mapping and have concluded it strongly indicates \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\". Considering the NF1 diagnosis context, this seems the most appropriate. I've confirmed both the diagnosis and assay mappings. Now, I'm ready to construct the output JSON, ensuring all data is accurately represented according to the schema.\n\n\n**Concluding Tumor Mapping**\n\nAfter meticulously re-evaluating the \"MPN tumor\" mapping, I'm confident in settling on \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\". Considering the existing NF1 diagnosis and the nuances of the schemas, this expansion aligns best. I've re-verified the \"WGS\" assay mapping to \"whole genome sequencing\", and confirmed the \"ORPHA:636\" diagnosis as \"Neurofibromatosis type 1\". I'm ready to move forward and finalize the JSON output.\n\n\n**Validating Results Thoroughly**\n\nMy review of the mapping for \"ORPHA:636\" (Neurofibromatosis type 1) and \"WGS\" (whole genome sequencing) confirms their accuracy. After thorough assessment, I'm confident in the JSON output, which reflects these mappings. I believe the results are accurate and ready for implementation.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Defining the Correction Process**\n\nI'm currently focused on defining the correction process for metadata. I'm analyzing how to map the existing data to a target schema, specifically tackling the issue of correcting metadata values in a JSON object. The input JSON and the Target Schema are key elements of this process.\n\n\n**Validating Input Against Schema**\n\nI've been working on validating input data against the target schema, focusing on specific fields.  For the `diagnosis` field, \"ORPHA:636\" correctly maps to \"Neurofibromatosis type 1\".  Similarly, I've confirmed that \"WGS\" in the `assay` field maps to \"whole genome sequencing\".  Next up: the `tumor` field analysis.\n\n\n**Mapping Tumor Types Precisely**\n\nI'm now diving into the `tumor` field, specifically \"MPN tumor.\" Based on the target schema and the context of Neurofibromatosis, \"Malignant Peripheral Nerve Sheath Tumor\" (MPNST) appears to be the most likely mapping. While \"MPN\" can refer to Myeloproliferative Neoplasms (and that is in the schema), the tumor context strongly suggests MPNST, and I want to confirm that. I'm investigating the possibility of \"MPN tumor\" being shorthand or a typo, as it's common in this domain. I'm also ensuring that I don't overlook \"Juvenile Myelomonocytic Leukemia\" (JMML), another MPN, which might be in the schema also. I'll evaluate the full list of options again for confirmation.\n\n\n**Clarifying Tumor Ambiguity**\n\nI'm now wrestling with the \"MPN tumor\" mapping. Given the NF1 diagnosis, both MPNST and JMML are possibilities. Analyzing the abbreviation \"MPN tumor\", my current thinking leans toward \"Malignant Peripheral Nerve Sheath Tumor\" (MPNST) as the intended target, particularly since \"tumor\" implies a solid mass in these schemas, and MPNST is more commonly abbreviated this way. I've re-reviewed the schema and mappings to solidify this.\n\n\n**Solidifying the Tumor Mapping**\n\nI've been meticulously reviewing the \"MPN tumor\" mapping and have concluded it strongly indicates \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\". Considering the NF1 diagnosis context, this seems the most appropriate. I've confirmed both the diagnosis and assay mappings. Now, I'm ready to construct the output JSON, ensuring all data is accurately represented according to the schema.\n\n\n**Concluding Tumor Mapping**\n\nAfter meticulously re-evaluating the \"MPN tumor\" mapping, I'm confident in settling on \"Malignant Peripheral Nerve Sheath Tumor (MPNST)\". Considering the existing NF1 diagnosis and the nuances of the schemas, this expansion aligns best. I've re-verified the \"WGS\" assay mapping to \"whole genome sequencing\", and confirmed the \"ORPHA:636\" diagnosis as \"Neurofibromatosis type 1\". I'm ready to move forward and finalize the JSON output.\n\n\n**Validating Results Thoroughly**\n\nMy review of the mapping for \"ORPHA:636\" (Neurofibromatosis type 1) and \"WGS\" (whole genome sequencing) confirms their accuracy. After thorough assessment, I'm confident in the JSON output, which reflects these mappings. I believe the results are accurate and ready for implementation.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2566,
              "completion_tokens": 1644,
              "total_tokens": 4210,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 1596,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole genome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 2566,
          "output_tokens": 1644,
          "total_tokens": 4210
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 3,
        "input": {
          "diagnosis": "Von Recklinghausen's neurofibromatosis",
          "assay": "MRS",
          "tumorType": "NOS"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"magnetic resonance spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2567,
            "outputTokens": 1518,
            "totalTokens": 4085
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584236-EAyH1nBEQnCxh3fahHq0",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763584236,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"magnetic resonance spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Mapping Nomenclature**\n\nI'm working on mapping terminology. Currently, I'm focusing on translating synonyms to standard terms based on the Target Schema. I'm prioritizing accuracy and efficiency, refining the logic to handle complex synonyms. My goal is to streamline the process, creating a dependable and extensible framework for metadata correction.\n\n\n**Identifying Equivalents**\n\nI've successfully identified \"Neurofibromatosis type 1\" as the equivalent of \"Von Recklinghausen's neurofibromatosis\".  \"MRS\" also directly maps to \"magnetic resonance spectroscopy\" in the schema. I'm moving onto the tumor type and evaluating its options.  I'm exploring the nuances of the \"NOS\" term and its best fit within the existing options. My focus is on ensuring the mappings are clinically accurate.\n\n\n**Refining Mapping Choices**\n\nI'm currently wrestling with the \"NOS\" dilemma within tumor types. \"Unknown\" seems like the most straightforward mapping for an unqualified \"NOS\" input, given the implicit lack of specificity. \"Not Applicable\" might apply if there's no tumor present, and \"tumor\" itself is an option when type remains unspecified. I'm leaning toward a default of \"Unknown\" for simple \"NOS\" entries, but I'll continue evaluating context-dependent exceptions.\n\n\n**Revising 'Unknown' Mapping**\n\nI'm now fully committed to \"Unknown\" as the optimal mapping for \"NOS\" entries in the tumorType field. The schema doesn't offer \"Not Otherwise Specified,\" reinforcing \"Unknown\" as the best fit for unspecified types. I've re-evaluated \"MRS\", confirming its direct match to \"magnetic resonance spectroscopy.\" Contextual nuances are minimal. It fits best with our existing logic.\n\n\n**Constructing the Output**\n\nI'm finalizing the JSON structure now. I've double-checked all the possible `tumorType` options and confirmed that \"Unknown\" is the best fit for an unqualified \"NOS\" input, maintaining semantic accuracy. The logic is solid and straightforward.\n\n\n**Solidifying the Logic**\n\nI'm now fully committed to \"Unknown\" as the definitive mapping for \"NOS\" when the specific tumor type is not given. I've considered \"Not Applicable\", but it's more suitable for cases where a tumor isn't present, whereas \"Unknown\" accurately reflects an unspecified type. Examining \"MRS\" confirms its direct translation to \"magnetic resonance spectroscopy,\" and \"Von Recklinghausen's neurofibromatosis\" unambiguously maps to \"Neurofibromatosis type 1.\" This logic now results in a clean JSON object reflecting the mapping strategy.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Mapping Nomenclature**\n\nI'm working on mapping terminology. Currently, I'm focusing on translating synonyms to standard terms based on the Target Schema. I'm prioritizing accuracy and efficiency, refining the logic to handle complex synonyms. My goal is to streamline the process, creating a dependable and extensible framework for metadata correction.\n\n\n**Identifying Equivalents**\n\nI've successfully identified \"Neurofibromatosis type 1\" as the equivalent of \"Von Recklinghausen's neurofibromatosis\".  \"MRS\" also directly maps to \"magnetic resonance spectroscopy\" in the schema. I'm moving onto the tumor type and evaluating its options.  I'm exploring the nuances of the \"NOS\" term and its best fit within the existing options. My focus is on ensuring the mappings are clinically accurate.\n\n\n**Refining Mapping Choices**\n\nI'm currently wrestling with the \"NOS\" dilemma within tumor types. \"Unknown\" seems like the most straightforward mapping for an unqualified \"NOS\" input, given the implicit lack of specificity. \"Not Applicable\" might apply if there's no tumor present, and \"tumor\" itself is an option when type remains unspecified. I'm leaning toward a default of \"Unknown\" for simple \"NOS\" entries, but I'll continue evaluating context-dependent exceptions.\n\n\n**Revising 'Unknown' Mapping**\n\nI'm now fully committed to \"Unknown\" as the optimal mapping for \"NOS\" entries in the tumorType field. The schema doesn't offer \"Not Otherwise Specified,\" reinforcing \"Unknown\" as the best fit for unspecified types. I've re-evaluated \"MRS\", confirming its direct match to \"magnetic resonance spectroscopy.\" Contextual nuances are minimal. It fits best with our existing logic.\n\n\n**Constructing the Output**\n\nI'm finalizing the JSON structure now. I've double-checked all the possible `tumorType` options and confirmed that \"Unknown\" is the best fit for an unqualified \"NOS\" input, maintaining semantic accuracy. The logic is solid and straightforward.\n\n\n**Solidifying the Logic**\n\nI'm now fully committed to \"Unknown\" as the definitive mapping for \"NOS\" when the specific tumor type is not given. I've considered \"Not Applicable\", but it's more suitable for cases where a tumor isn't present, whereas \"Unknown\" accurately reflects an unspecified type. Examining \"MRS\" confirms its direct translation to \"magnetic resonance spectroscopy,\" and \"Von Recklinghausen's neurofibromatosis\" unambiguously maps to \"Neurofibromatosis type 1.\" This logic now results in a clean JSON object reflecting the mapping strategy.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2567,
              "completion_tokens": 1518,
              "total_tokens": 4085,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 1477,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 2567,
          "output_tokens": 1518,
          "total_tokens": 4085
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 4,
        "input": {
          "diagnosis": "does not apply",
          "assay": "IHC",
          "tumorType": "cNF"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunohistochemistry\",\n  \"tumorType\": \"Cutaneous Neurofibroma\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2562,
            "outputTokens": 639,
            "totalTokens": 3201
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584250-pio8PKxBRHQH2UmUe0bX",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763584250,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunohistochemistry\",\n  \"tumorType\": \"Cutaneous Neurofibroma\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Analyzing Synonym Translation**\n\nI'm currently focused on the translation process. The goal is to accurately map synonymous terms found in the input data to a standardized vocabulary as defined by the Target Schema. I'm prioritizing efficient algorithms for this task, ensuring high accuracy while maintaining processing speed.\n\n\n**Mapping Defined Values**\n\nI've been working on defining mappings to the target schema. Specifically, I'm defining rules for the \"diagnosis\" and \"assay\" fields. For the `diagnosis` field, I mapped \"does not apply\" to \"Not Applicable\". Additionally, I identified that \"IHC\" in the `assay` field corresponds to \"immunohistochemistry\". I'm now expanding the rule-set to cover more input values across fields.\n\n\n**Refining Field Mappings**\n\nI've just added a new `tumorType` mapping. \"cNF\" maps directly to \"Cutaneous Neurofibroma\", based on its common abbreviation. The output JSON now includes this mapping, alongside the existing \"Not Applicable\" for diagnosis and \"immunohistochemistry\" for assay. A final schema validation confirmed all output values are within their allowed enums, signifying logical consistency.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Analyzing Synonym Translation**\n\nI'm currently focused on the translation process. The goal is to accurately map synonymous terms found in the input data to a standardized vocabulary as defined by the Target Schema. I'm prioritizing efficient algorithms for this task, ensuring high accuracy while maintaining processing speed.\n\n\n**Mapping Defined Values**\n\nI've been working on defining mappings to the target schema. Specifically, I'm defining rules for the \"diagnosis\" and \"assay\" fields. For the `diagnosis` field, I mapped \"does not apply\" to \"Not Applicable\". Additionally, I identified that \"IHC\" in the `assay` field corresponds to \"immunohistochemistry\". I'm now expanding the rule-set to cover more input values across fields.\n\n\n**Refining Field Mappings**\n\nI've just added a new `tumorType` mapping. \"cNF\" maps directly to \"Cutaneous Neurofibroma\", based on its common abbreviation. The output JSON now includes this mapping, alongside the existing \"Not Applicable\" for diagnosis and \"immunohistochemistry\" for assay. A final schema validation confirmed all output values are within their allowed enums, signifying logical consistency.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2562,
              "completion_tokens": 639,
              "total_tokens": 3201,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 599,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Not Applicable",
          "assay": "immunohistochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2562,
          "output_tokens": 639,
          "total_tokens": 3201
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 5,
        "input": {
          "diagnosis": "NF-1",
          "assay": "cell survival assay",
          "tumorType": "dermal neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Cutaneous Neurofibroma\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2566,
            "outputTokens": 522,
            "totalTokens": 3088
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584257-nhbudjzIKQswioVdhIAt",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763584257,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Cutaneous Neurofibroma\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Mapping Synonyms to Standards**\n\nI've been working on standardizing those metadata entries. Specifically, I'm focusing on translating synonyms for `diagnosis`, `assay`, and `tumorType` into the terms defined within the Target Schema. So far, I've successfully mapped the \"NF-1\" diagnosis. Now I am working on the mapping for \"cell survival assay\" and \"dermal neurofibroma\", based on established Target Schema term definitions.\n\n\n**Defining Assay & TumorType**\n\nI've finalized the mapping of \"cell survival assay\" to \"cell viability assay\". Additionally, I confirmed \"dermal neurofibroma\" maps to \"Cutaneous Neurofibroma\", aligning with standard medical terminology. Now I'm reviewing the schema to ensure consistent output format. The planned output now stands: `diagnosis`: \"Neurofibromatosis type 1\", `assay`: \"cell viability assay\", `tumorType`: \"Cutaneous Neurofibroma\".\n\n\n**Finalizing the Output Format**\n\nI've verified the data now conforms to the intended JSON structure. All key-value pairs are exact matches to standardized terms. The output now is fully validated: {\"diagnosis\": \"Neurofibromatosis type 1\", \"assay\": \"cell viability assay\", \"tumorType\": \"Cutaneous Neurofibroma\"}. This structure is now consistent, adhering to the established schema rules.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Mapping Synonyms to Standards**\n\nI've been working on standardizing those metadata entries. Specifically, I'm focusing on translating synonyms for `diagnosis`, `assay`, and `tumorType` into the terms defined within the Target Schema. So far, I've successfully mapped the \"NF-1\" diagnosis. Now I am working on the mapping for \"cell survival assay\" and \"dermal neurofibroma\", based on established Target Schema term definitions.\n\n\n**Defining Assay & TumorType**\n\nI've finalized the mapping of \"cell survival assay\" to \"cell viability assay\". Additionally, I confirmed \"dermal neurofibroma\" maps to \"Cutaneous Neurofibroma\", aligning with standard medical terminology. Now I'm reviewing the schema to ensure consistent output format. The planned output now stands: `diagnosis`: \"Neurofibromatosis type 1\", `assay`: \"cell viability assay\", `tumorType`: \"Cutaneous Neurofibroma\".\n\n\n**Finalizing the Output Format**\n\nI've verified the data now conforms to the intended JSON structure. All key-value pairs are exact matches to standardized terms. The output now is fully validated: {\"diagnosis\": \"Neurofibromatosis type 1\", \"assay\": \"cell viability assay\", \"tumorType\": \"Cutaneous Neurofibroma\"}. This structure is now consistent, adhering to the established schema rules.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "EqcQCqQQAdHtim+tbxD9jWalFxdi1frt2wqYtn8qNGq67QUB4Vf0NXBqeWWoFzE07feCBKzZccwclPkt7pTHL6cbT5zOBVCh0j3slwtnTrwbLXw+Y166DVRVU4Ca7dXaLN38oL+f7tXOluKpyXdqWsl/bWmToj5201aBT0XV/FImwCUS09BUSBRDU46V70RZrn5z7t5bgYXSyKbZtnsmdy/Y29oEoKzPTtyjoG8W6VMqb+dQDMBsL7/jCZHfBBsXxWjF098cp0YdZXJOv+gaEQp5O/Ua1vbAWRmGq4Qy01DwGHHicIlSoGaeEK6K4Ix+3FFTsx/8P7jN6IbGWkqFxPZDhlc5BK/rZUUHDfMFgwL5a794llpK2OfJi29gNQxrncAUnAuIed7QRMQ+RF0NNrePT+67DHuB9PU1bvAnfSHrJJKG+nuiwyZB/+YRru15/FBvsFR2RpsmoQvTtjBc+8qNi5nfua+OYQNYJyQn+ky0sHiRRvJKS7pj0xViXeFzGE9m9xHWr3Q8a2+OB7A9puNHp+e0ke9T1fsuO6D5jt/VIjSWWVNYbK1wjEKxr7YiWzb7jNYqJma3bQVULHIrnh87pOSDCmwpUvSdmNKE16pkF9rUax7LhGYzXeLY/8pHq/Y+4rwwBCWHzrj6VrILp/Gv2EsoxOOlJQeF5Ajk6JQoF2xip0+MVKDX24iCSp/6khJjFMEpnKXIWQpIgbbweIiptqP2yrSw4zaUdegJ/Wi1GaEO31On55gC0XRVBRFUf2xcDHfGsLablwUFVeRgLw5CBUhhcoOiyz+dzPO+f+ajHB9I56BCEfPbbBLIIJ3uNOw3Vq0PwldYXKBaZkhb1/BKhxkSqZEtC4ENWpaNPxppNxHUGsuWo7nb26KRa9f8yrI9/jrnCGimZB2STqo8NugpQ0HaLxJ4gjVSHqthfDXw295DLQXNTvSljlVUraMh+SEDLe4maBXSso4GZzBKTog0VPIWZmiwW/TEHx0IAjzzIkYET5odpi4bqFuIIiav3hhIUprqflK+Dqi8RE8Vplrwd7YU1TAyrRs51Ny8iNUQLbhXdb6nMqpB2upoRPR9Pcrp0323R9+KtBD5hNZKXxQgrBQp8kkROzeSRedn9n8RCkUBD2IGdmZoH5xuOrk0xpQIHcKt3MzndnFOGqgsGLDQJ9nXt0bJoBMgR6XcB1EhT23WHPyjc30gkSYgWLVfv87JtHVd8q5BBmsa2Z/c/SQUe8EpBgfnZkcdvmNcwS1Ox0nMSMzd2mQGgtzYGTf9KC3gVH6yaE3AQOl8WB8u9+GLRWPE+1s5UWcfaGsTTIW+I3OIjqZk33t3+r8qXkMef9c8KsUzljUUW8WbABFBIvys2RdHl83J5D/zizPPKljKr0voRqhqpkYdLy1K3xr2c+M3lvEo3Ll69ECFMwvdz4W4oAoqx9C8jlR8lgloA1gU5Two9i83QPXjyKjTWD+X0WbIN83ReFQXyOBoz2XB9B2g2dn2CyK/Oj5CE5pBEmFGNsN5bvrnu36kGbPemIu81pitwN9FxiwjcCXYMlvpJNckrflJHQUC9/7gE/wtGBYPULnuNVTyAv1McNtPFn3xVZvrugE5CjRoFxmWGAaF8gP6eyFkiyjL+s0BH5uACeLqcWcQrU+ykm7Tlj3U00YhZWPZAW626uuCLtslfFZnwvFU7UtI6m7mdJ07d1bFs4r8ZZYAe0Y3MwB8a+0pCusQ7w9ov2DPdDFgBEcOzvVSl1uwAaWkFD/w/ArXLyC17MvG58okYoK3y/vdfb3Grq8M3bMC6HZYxn15zv43bq+EEe6d37SuQ3GVeFOZmBIAdJVci4MMQhaYkmBkvct+HgwAQEz72SODZSbqXMYrTFR7Byvp/Fs2sOFMG4MAqDyI4cEpeidCb9xdwsFFjpxZloph1QDtJdhYBF/812VrYbu/2HlENu6x4rOf+DuSehWYWhGuv1Cum7KKn2oi0ZZ1d8SLHthh0DY9MeliT3pkAQkbZeBrcadhG5ARH6zvQSIj3qOWboj5RdRFTETRk9J5z6tJnpvcXlpk0+fM68rs8SWJObcaDMG7xkRBh5smj3hwHQhCswtolO71Biz02NM2GoA466C6qRifCeHBJt1LkozQfY86foINDtBHZE8WMWG3XsHJSFYIpKK7IOtpr1UAaQl3jkWOqY47OUv3lFmLKvrWCjLcLil6XzO0eXkKK1q8mW29eq5pMBnW4VsdGb+7gRl3Q2nK+klqmYX7X1KtJDlevmAiv1jvv+D6NnkaV/ww/FWZlZyPNUSZtMo3Fm9NB7byQz9kCmGuSS6XSkV7tmOej4BEX+NrlvkuE7GxxT5mfy4D4PspdO/LbqXk7PGlpG+vbpjAotEN6xe3bgtEn+a1V2R4T8Z4hNUOWxKyK4vxvPiiknwc8aGpOfpGcEgy4LInV3fq5wY0XO+3AZsK2yJp0sGimOLddyrRlTh1QjiP5VmmOsXfYM/mEUhNiQc6ZUdrac/8JC37vXlKHRODBM5m9F9aYiof3WPvxacK42Q2lpR7tw5mJpScXZwWKEF0X29QcciFYaCLpSJSAntzrRgPQ8jIhddiX4eEb0c76S+ySdY/IpAlo7PfJk8ryk/DzdcSrJJeMvzCH4kKjO5GO4QUJZ33zp6kjG1BfX4mmLJF4/UZK4P0xGjcySnK1oVC/tFQgKOE7BPPVWsDHIo+V8V+A9l2Fb2Xreo/VjadWf0M5BWkronMVBX8fvMKP/OtCjRmAUKsv03GIJztverBo8al9wxvRC1zl/DvWSM="
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2566,
              "completion_tokens": 522,
              "total_tokens": 3088,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 477,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "cell viability assay",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2566,
          "output_tokens": 522,
          "total_tokens": 3088
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 6,
        "input": {
          "diagnosis": "neurofibromatosis 1",
          "assay": "ICC",
          "tumorType": "localized neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunocytochemistry\",\n  \"tumorType\": \"Localized Neurofibroma\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2566,
            "outputTokens": 464,
            "totalTokens": 3030
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584263-gA7EAxBV2zYlgEI62x6x",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763584263,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunocytochemistry\",\n  \"tumorType\": \"Localized Neurofibroma\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Analyzing Input for Translation**\n\nI'm currently focused on the input data. I've begun to analyze the provided JSON, specifically examining the 'diagnosis', 'assay', and 'tumorType' fields. My initial assessment is geared towards identifying potential synonym-to-standard term translations needed according to the Target Schema. I am planning on evaluating each field against the target schema and making a mapping for the needed translations.\n\n\n**Confirming Target Values**\n\nI've solidified my translation mappings for the provided input.  Specifically, I've confirmed that \"neurofibromatosis 1\" correctly translates to \"Neurofibromatosis type 1\". \"ICC\" is mapped to \"immunocytochemistry\" and \"localized neurofibroma\" is mapped to \"Localized Neurofibroma\", simply needing a case correction. I'm now certain these values meet the target schema requirements and ready for final output.\n\n\n**Validating Target Schema Compliance**\n\nI've verified that the values \"ICC\" and \"Localized Neurofibroma\" both adhere to the schema's enumerated values. My analysis confirms that the prior translations for these fields were accurate and consistent with the intended target structure. This validates the final output as ready.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Analyzing Input for Translation**\n\nI'm currently focused on the input data. I've begun to analyze the provided JSON, specifically examining the 'diagnosis', 'assay', and 'tumorType' fields. My initial assessment is geared towards identifying potential synonym-to-standard term translations needed according to the Target Schema. I am planning on evaluating each field against the target schema and making a mapping for the needed translations.\n\n\n**Confirming Target Values**\n\nI've solidified my translation mappings for the provided input.  Specifically, I've confirmed that \"neurofibromatosis 1\" correctly translates to \"Neurofibromatosis type 1\". \"ICC\" is mapped to \"immunocytochemistry\" and \"localized neurofibroma\" is mapped to \"Localized Neurofibroma\", simply needing a case correction. I'm now certain these values meet the target schema requirements and ready for final output.\n\n\n**Validating Target Schema Compliance**\n\nI've verified that the values \"ICC\" and \"Localized Neurofibroma\" both adhere to the schema's enumerated values. My analysis confirms that the prior translations for these fields were accurate and consistent with the intended target structure. This validates the final output as ready.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "EucNCuQNAdHtim/NxzBjEQ5cgotsHkVkSP3mSLKgKLYwjn4hdGRW8mupqjZGvIunQOurPsUI0EPp3RpHhExV3rk/m/RRLUzNHaDT1/cTAYMUe+YWHr5Rbm8El8xQ1c6AC5w+o1Sq5AVoQRyDVuodJpiInHyDCePvYgOLN8NHyQdwBdMuGcXatC88OE/BkkjJ5Gx04AfswMo6jxBgtDpFoHjkbLAFhnLrUQI3YdGocN73gCV+7JkSUEsObAwEXE+5zlm4zBUZf3aPKAi+XZg7gTdFW1S0FKY3ST4Iszn9rahi6OPReQATUN80FkVcVgPaJh/IQpo9JDuPmvdvEfdATuNBYYMQ7dEA0WzsM64OT/OsBikHJaX6Qqogm2gHzWIFk1tU8YeTbbWwyAw/uJ7KKZrUROTwjCQfyJ/+iC0drshdAEIbUHeuUSLT/DBD9TCWM8voxYDhomvXbAd6sSbtbHkF5rNIDR3ZQTM2sAh78tGeUhiq/+Qdp0dOsyiW/akszbg47NtHcS6be0nPBhIM6Nx1S0pHb5MzegI6pKNDpld5t44hlhbGvAYwxKvMe8YZ5YSGo/tmusF7XyMzD5clN4gFlKZSOgCUJylSCjSdnmg7PKT2CCxZJPSGYrlzw6os7e1AAMKMbd3jImSbyY574MtHfZ8eVonTBh37CJ+I2Iqy3bd8JhMaIkNyejYpFR1i5nPyedp7QQHXCbH2qXIxjaHwniaXB+p0basHpqh4ZbmbSt/0do2A/uZ/jnBLLq7GZYbTKq/DBAu88cYSZ/BxS8LmMrTxqNQO2g3F9BbH0LfuItI9M0bbK5SvF5tVD2lhyM6hqg7fL2PHJVhz7GtQ7fe3Ol5oQKG/5GF2ZTTDt46kHoWIddwOF1BWRAyYAh1EjjIKfstxiNlS8fgz/tt3ylI4okeJugxsMsoaUy03gz2iJn9/TSxultVucodrHEhU4TrvITdcA4OkTCnttwpBgtSORKS6KfTidJpuAcQZ9wwUrkXLBGLB2b/X0Z1iK/Ne91ZxvXvJ/AsrII4ztcyX5WXHGndWu8QaG5Qs1y9WBU8sIa4OHNz5pQWTSGhGxDVkgXuZYreGtE72ffNgypCgiTOX/dq+aVQIIoD9ArL+Iy6kD5ciYmmaDBKErzXnTnNf1N44qwHatNIRuFRE+wkJZtaECGLv2ZckGU6QJkKnZCDajxFqhm0NdKSi80Uqjmve28SmzArZrAfCSeDuSOXVoKGZIILVQE0dYedCuu2Z9WQWI9oh6O3Jtxz+8ALwZBn/f7tb3Uf9ErRAgc/Q5YuToFybjgpTFPTTyzM3Xu3W5MR45dC89JYJgUE9W6VpwPckNdXxb013Fq4/sREi1B+Hx7o99TvimnI8uBTO37ljCmDyHXiy8XlDVq1Tpx4GpnOutOvZ43vJVbVqWTdt98bV2qDDAibnPRBc4PfI99a6+QC0jDzryjfSwIIDHWVYO7/N34t1u93I4PIKsTyz1NFAy8+UK8k8Wv+wxtzmqwSJpalkPfBXif+gkhNOvLvc2kZSz46U3lxTXvZUMNhPzLJnk5aiT39y4nhnphFa2Ifv0YaF3+Yag3gKCnV+57wBU3JeEHf7bU8h/X7OemkDYtJbhDV3Bj7Cr9hNH3faAJmzd4xfFm63y4/trNczDCLBVOUUDVeimTBRT4MeMeijb9hAe2dmVsgSRXzXBcD6Vjree2vcIZMhwW0Z4U1VEv1oEhsPVZhB4b43e8V1YKNjl0FNBI3DRYFRb+QUel2y0gU2TonmzjkO2ITWcxPWF/m8uaaRgpM+3Oc+m3xm6Xq6d+SydgD3P+rzBs2UKx4pWQ2FiJvRv0TukQbprAXy/uI+WpiA2Bn7u8N5RLB/+GxpN663MOD+uV3Rkeu/8dZzf8oOQOxqoFKv3Tz8Bqletr1IsoOodMR4dXhAj6Ho7Ito/dIt/JaE1NzomWp2PRPw4vrHZ9FkWuFiy+Rjnooi4VmMQfYqjfuUcZE+dLLkgjFPK3vaUNwQMnygArl0PAHxHmDXyX8GTFIUNLDx+vTLi8LAeOnc2uVBlMh9VWnkW2jBqZO0MemDxzBqLm4SwZDlnFnJaaPVJGBaggIFr31wM1huE1S74IYY886D7CsW3UDPC24ZJf9jJCejyWRwJMoT2dYs/x1Dq6Vbx2zBm22+QaaQ0BbUXNcSrfvDsSL6GyeR1jF9+MevJ2KTlVsnYy4CzxVffym6JOAd1S7XVB63q2kJkd9LEJwQp9c1UEkDY1w7KTmz9Xw/XLUKyMz5Sq+mopsdQd2UeKXGUl/fZi2lqsgRZAEVbzjzF9sgDYJmQv8TbtA1r86ko2yqyOvPKhUPXr+8TJUhqxUgI0vGqXkU"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2566,
              "completion_tokens": 464,
              "total_tokens": 3030,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 420,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "immunocytochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 2566,
          "output_tokens": 464,
          "total_tokens": 3030
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 7,
        "input": {
          "diagnosis": "Neurofibromatosis-1",
          "assay": "magnetic resonance imaging",
          "tumorType": "not determined"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"structural MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2566,
            "outputTokens": 2747,
            "totalTokens": 5313
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584268-MRRIz8DEy3nbnIvaEYpC",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763584268,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"structural MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Mapping Synonymy**\n\nOkay, I'm working on the data mapping.  I see \"Neurofibromatosis-1\" as a diagnosis and \"magnetic resonance imaging\" for the assay. \"TumorType: not determined\" seems a bit tricky.  I need to clarify if \"not determined\" maps to a standard term in the Target Schema.  I'm also considering potential variations and synonyms of the listed entries.\n\n\n**Analyzing Terminology Mappings**\n\nI've just finished the analysis of the `diagnosis` field. It was straightforward, thankfully. \"Neurofibromatosis-1\" maps directly to the standard term \"Neurofibromatosis type 1\" within the target schema. I am now looking at the `assay` field and noting \"magnetic resonance imaging\" isn't a direct match, but \"Magnetization-Prepared Rapid Gradient Echo MRI\" seems relevant. I'll need to determine the level of granularity required for the mapping.\n\n\n**Exploring MRI Specificity**\n\nI'm now diving deeper into the nuances of \"magnetic resonance imaging\" and its subtypes. I see \"structural MRI\" is a common standard mapping, but the list also includes other MRI techniques like \"conventional MRI\" and \"Magnetization-Prepared Rapid Gradient Echo MRI.\" The question is, should I generalize to \"MRI\" if no specifics are provided, or choose the best fit from the list? I'm re-evaluating if I need to identify the implicit type from the context.\n\n\n**Reconciling MRI Subtypes**\n\nI'm now focusing on the varied MRI techniques listed. I've considered several options like \"diffusion MRI\", \"functional MRI\", and \"magnetic resonance angiography\".  \"Structural MRI\" and \"conventional MRI\" are the most common in this context, especially in NF datasets. I think \"structural MRI\" is the best default mapping, given the lack of specific details, but I also need to account for \"conventional MRI\" as an alternative.\n\n\n**Determining Mapping Defaults**\n\nI'm now revisiting the \"assay\" field and its relationship with the available MRI subtypes. I'm focusing on refining the mapping rule, considering \"structural MRI\" as the default for \"magnetic resonance imaging\" since it is the most common anatomical imaging technique. I'm also now considering \"conventional MRI\" as an alternative due to its frequent use in related datasets. I am also planning to review \"diffusion MRI\", \"functional MRI\", \"resting state functional MRI\", \"magnetic resonance angiography\" (MRA), and \"magnetic resonance spectroscopy\" (MRS) mappings. I'll need to account for all of these.\n\n\n**Resolving `tumorType`**\n\nI'm now focusing on the `tumorType` field. The \"not determined\" input leads me to the \"Unknown\" value from the target schema's controlled vocabulary. I've re-examined the context of the data and determined that \"Unknown\" is the most appropriate mapping, rather than \"Not Applicable\". I'm also confirming that the `assay` values are well defined.\n\n\n**Concluding the Mappings**\n\nI've finalized my thinking on the mappings. \"Neurofibromatosis-1\" maps perfectly to \"Neurofibromatosis type 1\", and \"not determined\" cleanly maps to \"Unknown.\" I've decided that \"structural MRI\" is the best fit for \"magnetic resonance imaging\", after considering \"conventional MRI.\" I've considered all possible mapping options. I'm now certain of these conclusions.\n\n\n**Validating Final Outputs**\n\nI'm now satisfied with the final mapping. Reflecting on the \"assay\" field, my initial inclination was to use a broader term, but after carefully reviewing the ontology and the context, \"structural MRI\" feels like the best choice. This choice is supported by the context of the list that contains \"functional MRI\" and \"conventional MRI\". The \"tumorType\" field is also clear, \"Unknown\" is the most appropriate mapping for \"not determined\". The JSON output is well-formed.\n\n\n**Solidifying Mapping Choices**\n\nI'm revisiting the \"assay\" field with a refined perspective. Considering the specific MRI techniques listed: \"MP-RAGE\", \"diffusion MRI\", \"functional MRI\", \"magnetic resonance angiography,\" \"magnetic resonance spectroscopy,\" and \"resting state functional MRI,\" I've confirmed that \"structural MRI\" is the optimal mapping for \"magnetic resonance imaging\" in this context, given the anatomical focus and the available granularity. I am confident in selecting \"structural MRI\" as the definitive choice.\n\n\n**Refining Assay Mapping**\n\nI'm revisiting the \"assay\" field with a refined perspective. Considering the specific MRI techniques listed, I've confirmed that \"structural MRI\" remains the optimal mapping for \"magnetic resonance imaging\" in this context, given the anatomical focus and the available granularity. I am confident in selecting \"structural MRI\" as the definitive choice.\n\n\n**Selecting 'structural MRI'**\n\nI've been re-evaluating the \"assay\" field, considering the provided MRI techniques and the target schema. After a thorough review, I'm confident that \"structural MRI\" is the best fit for \"magnetic resonance imaging\", despite the presence of \"conventional MRI.\" \"Structural MRI\" represents the standard and most generic subclass in this context. \"Unknown\" remains the correct mapping for \"not determined\" in `tumorType`. The final mappings are now solidified, and I am satisfied with the result.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Mapping Synonymy**\n\nOkay, I'm working on the data mapping.  I see \"Neurofibromatosis-1\" as a diagnosis and \"magnetic resonance imaging\" for the assay. \"TumorType: not determined\" seems a bit tricky.  I need to clarify if \"not determined\" maps to a standard term in the Target Schema.  I'm also considering potential variations and synonyms of the listed entries.\n\n\n**Analyzing Terminology Mappings**\n\nI've just finished the analysis of the `diagnosis` field. It was straightforward, thankfully. \"Neurofibromatosis-1\" maps directly to the standard term \"Neurofibromatosis type 1\" within the target schema. I am now looking at the `assay` field and noting \"magnetic resonance imaging\" isn't a direct match, but \"Magnetization-Prepared Rapid Gradient Echo MRI\" seems relevant. I'll need to determine the level of granularity required for the mapping.\n\n\n**Exploring MRI Specificity**\n\nI'm now diving deeper into the nuances of \"magnetic resonance imaging\" and its subtypes. I see \"structural MRI\" is a common standard mapping, but the list also includes other MRI techniques like \"conventional MRI\" and \"Magnetization-Prepared Rapid Gradient Echo MRI.\" The question is, should I generalize to \"MRI\" if no specifics are provided, or choose the best fit from the list? I'm re-evaluating if I need to identify the implicit type from the context.\n\n\n**Reconciling MRI Subtypes**\n\nI'm now focusing on the varied MRI techniques listed. I've considered several options like \"diffusion MRI\", \"functional MRI\", and \"magnetic resonance angiography\".  \"Structural MRI\" and \"conventional MRI\" are the most common in this context, especially in NF datasets. I think \"structural MRI\" is the best default mapping, given the lack of specific details, but I also need to account for \"conventional MRI\" as an alternative.\n\n\n**Determining Mapping Defaults**\n\nI'm now revisiting the \"assay\" field and its relationship with the available MRI subtypes. I'm focusing on refining the mapping rule, considering \"structural MRI\" as the default for \"magnetic resonance imaging\" since it is the most common anatomical imaging technique. I'm also now considering \"conventional MRI\" as an alternative due to its frequent use in related datasets. I am also planning to review \"diffusion MRI\", \"functional MRI\", \"resting state functional MRI\", \"magnetic resonance angiography\" (MRA), and \"magnetic resonance spectroscopy\" (MRS) mappings. I'll need to account for all of these.\n\n\n**Resolving `tumorType`**\n\nI'm now focusing on the `tumorType` field. The \"not determined\" input leads me to the \"Unknown\" value from the target schema's controlled vocabulary. I've re-examined the context of the data and determined that \"Unknown\" is the most appropriate mapping, rather than \"Not Applicable\". I'm also confirming that the `assay` values are well defined.\n\n\n**Concluding the Mappings**\n\nI've finalized my thinking on the mappings. \"Neurofibromatosis-1\" maps perfectly to \"Neurofibromatosis type 1\", and \"not determined\" cleanly maps to \"Unknown.\" I've decided that \"structural MRI\" is the best fit for \"magnetic resonance imaging\", after considering \"conventional MRI.\" I've considered all possible mapping options. I'm now certain of these conclusions.\n\n\n**Validating Final Outputs**\n\nI'm now satisfied with the final mapping. Reflecting on the \"assay\" field, my initial inclination was to use a broader term, but after carefully reviewing the ontology and the context, \"structural MRI\" feels like the best choice. This choice is supported by the context of the list that contains \"functional MRI\" and \"conventional MRI\". The \"tumorType\" field is also clear, \"Unknown\" is the most appropriate mapping for \"not determined\". The JSON output is well-formed.\n\n\n**Solidifying Mapping Choices**\n\nI'm revisiting the \"assay\" field with a refined perspective. Considering the specific MRI techniques listed: \"MP-RAGE\", \"diffusion MRI\", \"functional MRI\", \"magnetic resonance angiography,\" \"magnetic resonance spectroscopy,\" and \"resting state functional MRI,\" I've confirmed that \"structural MRI\" is the optimal mapping for \"magnetic resonance imaging\" in this context, given the anatomical focus and the available granularity. I am confident in selecting \"structural MRI\" as the definitive choice.\n\n\n**Refining Assay Mapping**\n\nI'm revisiting the \"assay\" field with a refined perspective. Considering the specific MRI techniques listed, I've confirmed that \"structural MRI\" remains the optimal mapping for \"magnetic resonance imaging\" in this context, given the anatomical focus and the available granularity. I am confident in selecting \"structural MRI\" as the definitive choice.\n\n\n**Selecting 'structural MRI'**\n\nI've been re-evaluating the \"assay\" field, considering the provided MRI techniques and the target schema. After a thorough review, I'm confident that \"structural MRI\" is the best fit for \"magnetic resonance imaging\", despite the presence of \"conventional MRI.\" \"Structural MRI\" represents the standard and most generic subclass in this context. \"Unknown\" remains the correct mapping for \"not determined\" in `tumorType`. The final mappings are now solidified, and I am satisfied with the result.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2566,
              "completion_tokens": 2747,
              "total_tokens": 5313,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 2707,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 2566,
          "output_tokens": 2747,
          "total_tokens": 5313
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 8,
        "input": {
          "diagnosis": "NF2",
          "assay": "RNA sequencing",
          "tumorType": "benign neurilemmoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"NF2-related schwannomatosis\",\n  \"assay\": \"RNA-seq\",\n  \"tumorType\": \"Schwannoma\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2565,
            "outputTokens": 580,
            "totalTokens": 3145
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584292-oAfkKKMJSTTkOpmp0AMA",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763584292,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"NF2-related schwannomatosis\",\n  \"assay\": \"RNA-seq\",\n  \"tumorType\": \"Schwannoma\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Mapping Key Concepts**\n\nI'm currently focused on mapping the input concepts to the target schema. \"NF2\" likely corresponds to a specific genetic diagnosis within the schema. \"RNA sequencing\" needs accurate alignment with an assay standard. Lastly, the tumor type \"benign neurilemmoma\" needs translation to a standardized term, accounting for any nuances in the target terminology.\n\n\n**Confirming Mappings**\n\nI've solidified the mappings for key fields. \"NF2\" now definitively translates to \"NF2-related schwannomatosis.\" \"RNA sequencing\" is consistently mapped to \"RNA-seq\" based on common usage. Finally, \"benign neurilemmoma\" is confirmed as \"Schwannoma\", considering it's a synonym.\n\n\n**Finalizing JSON Output**\n\nI've validated the final JSON output against the schema's enumerated values. \"NF2-related schwannomatosis,\" \"RNA-seq,\" and \"Schwannoma\" are all permissible options, ensuring the data's integrity and adherence to the schema requirements. The final output is ready.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Mapping Key Concepts**\n\nI'm currently focused on mapping the input concepts to the target schema. \"NF2\" likely corresponds to a specific genetic diagnosis within the schema. \"RNA sequencing\" needs accurate alignment with an assay standard. Lastly, the tumor type \"benign neurilemmoma\" needs translation to a standardized term, accounting for any nuances in the target terminology.\n\n\n**Confirming Mappings**\n\nI've solidified the mappings for key fields. \"NF2\" now definitively translates to \"NF2-related schwannomatosis.\" \"RNA sequencing\" is consistently mapped to \"RNA-seq\" based on common usage. Finally, \"benign neurilemmoma\" is confirmed as \"Schwannoma\", considering it's a synonym.\n\n\n**Finalizing JSON Output**\n\nI've validated the final JSON output against the schema's enumerated values. \"NF2-related schwannomatosis,\" \"RNA-seq,\" and \"Schwannoma\" are all permissible options, ensuring the data's integrity and adherence to the schema requirements. The final output is ready.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2565,
              "completion_tokens": 580,
              "total_tokens": 3145,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 536,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "NF2-related schwannomatosis",
          "assay": "RNA-seq",
          "tumorType": "schwannoma"
        },
        "token_usage": {
          "input_tokens": 2565,
          "output_tokens": 580,
          "total_tokens": 3145
        },
        "tool_calls": [],
        "tool_execution_history": []
      },
      {
        "sample_index": 9,
        "input": {
          "diagnosis": "Nonmosaic NF1",
          "assay": "3D microtissue survival assay",
          "tumorType": "neurofibrosarcoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"3D microtissue viability\",\n  \"tumorType\": \"Malignant Peripheral Nerve Sheath Tumor\"\n}\n```",
          "model_id": "google/gemini-3-pro-preview",
          "usage": {
            "inputTokens": 2570,
            "outputTokens": 681,
            "totalTokens": 3251
          },
          "attempt": 1,
          "raw_response": {
            "id": "gen-1763584298-s0B1CXA7BSjI3EvfflLN",
            "provider": "Google AI Studio",
            "model": "google/gemini-3-pro-preview",
            "object": "chat.completion",
            "created": 1763584298,
            "choices": [
              {
                "logprobs": null,
                "finish_reason": "stop",
                "native_finish_reason": "STOP",
                "index": 0,
                "message": {
                  "role": "assistant",
                  "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"3D microtissue viability\",\n  \"tumorType\": \"Malignant Peripheral Nerve Sheath Tumor\"\n}\n```",
                  "refusal": null,
                  "reasoning": "**Refining Schema Alignment**\n\nI'm currently working on aligning the input data with the Target Schema. I'm focusing on validating field values against the defined enums and mapping any synonyms to their corresponding canonical values. The goal is to ensure data integrity and compliance with the Target Schema.\n\n\n**Analyzing Assay Details**\n\nI've determined that \"Nonmosaic NF1\" should map to \"Neurofibromatosis type 1\" for diagnosis. For the assay details, \"3D microtissue survival assay\" seems equivalent to \"3D microtissue viability\" based on the Target Schema. I'm moving forward by extracting and mapping the data values, ensuring consistency with the Target Schema. I am also identifying and mapping synonyms to ensure proper alignment.\n\n\n**Verifying Output Data**\n\nI have successfully mapped the input \"neurofibrosarcoma\" to \"Malignant Peripheral Nerve Sheath Tumor\", which aligns perfectly with the Target Schema. \"Tissue survival assay\" maps precisely to the schema's \"3D microtissue viability.\" The output now comprises the correct enum values: \"Neurofibromatosis type 1,\" \"3D microtissue viability,\" and \"Malignant Peripheral Nerve Sheath Tumor.\" I've performed a final verification to confirm all values adhere to the specified schema enums.\n\n\n",
                  "reasoning_details": [
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.text",
                      "text": "**Refining Schema Alignment**\n\nI'm currently working on aligning the input data with the Target Schema. I'm focusing on validating field values against the defined enums and mapping any synonyms to their corresponding canonical values. The goal is to ensure data integrity and compliance with the Target Schema.\n\n\n**Analyzing Assay Details**\n\nI've determined that \"Nonmosaic NF1\" should map to \"Neurofibromatosis type 1\" for diagnosis. For the assay details, \"3D microtissue survival assay\" seems equivalent to \"3D microtissue viability\" based on the Target Schema. I'm moving forward by extracting and mapping the data values, ensuring consistency with the Target Schema. I am also identifying and mapping synonyms to ensure proper alignment.\n\n\n**Verifying Output Data**\n\nI have successfully mapped the input \"neurofibrosarcoma\" to \"Malignant Peripheral Nerve Sheath Tumor\", which aligns perfectly with the Target Schema. \"Tissue survival assay\" maps precisely to the schema's \"3D microtissue viability.\" The output now comprises the correct enum values: \"Neurofibromatosis type 1,\" \"3D microtissue viability,\" and \"Malignant Peripheral Nerve Sheath Tumor.\" I've performed a final verification to confirm all values adhere to the specified schema enums.\n\n\n"
                    },
                    {
                      "format": "google-gemini-v1",
                      "index": 0,
                      "type": "reasoning.encrypted",
                      "data": "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"
                    }
                  ]
                }
              }
            ],
            "usage": {
              "prompt_tokens": 2570,
              "completion_tokens": 681,
              "total_tokens": 3251,
              "prompt_tokens_details": {
                "cached_tokens": 2027
              },
              "completion_tokens_details": {
                "reasoning_tokens": 631,
                "image_tokens": 0
              }
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "3D microtissue viability",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 2570,
          "output_tokens": 681,
          "total_tokens": 3251
        },
        "tool_calls": [],
        "tool_execution_history": []
      }
    ],
    "metrics": {
      "total_samples": 10,
      "successful_runs": 10,
      "failed_runs": 0,
      "success_rate": 1.0,
      "average_score": 0.8666666666666668,
      "min_score": 0.6666666666666666,
      "max_score": 1.0,
      "num_scored": 10
    },
    "duration_seconds": 96.53457641601562,
    "token_usage": {
      "input_tokens": 25655,
      "output_tokens": 10004,
      "total_tokens": 35659
    }
  }
}